zintick

Lyell Immunopharma LYEL

Lyell Immunopharma, Inc. · Nasdaq · Pharmaceutical Preparations

$16.86+0.66%close on Nov. 11, 2026 · volume 154K · Yahoo Finance

Price, last 57 sessions

$10.00$12.50$15.00Sept. 2026Oct. 2026Nov. 2026
Aug. 24, 2026 to Nov. 11, 2026 · high $16.86 · low $7.51 · SEC filing, placed when SEC released it

Our coverage

Insider buying and selling

DateInsiderTradeSharesAvg. priceValue
Nov. 4, 2026ARCH Venture Partners IX LLC
with ARCH Venture Fund IX L.P., ARCH Venture Partners IX L.P., ARCH Venture Fund IX Overage L.P., ARCH Venture Partners IX Overage L.P.
10% owner · indirect
Bought2,321,262$10.77$25.00 million
Nov. 4, 2026ARCH Venture Fund XIII L.P.
with ARCH Venture Partners XIII L.P., ARCH Venture Partners XIII LLC, Keith Crandell, Steven Gillis, Robert Nelsen, Kristina Burow, Paul L. Berns, Clinton Bybee
10% owner · indirect
Bought2,321,262$10.77$25.00 million
Oct. 12, 2026Jarrad Mattieu Aguirre
Chief Medical Officer
Sold422$8.63$3,642
Sept. 10, 2026David Shook
Chief Medical Officer
Sold500$12.70$6,350
Aug. 21, 2026Lynn Seely
President and CEO, director
Sold9,589$15.54$149,013
Aug. 21, 2026Stephen J. Hill
Chief Operating Officer
Sold989$15.54$15,369
Aug. 21, 2026Gary K. Lee
Chief Scientific Officer
Sold1,457$15.54$22,642
Aug. 10, 2026Veronica Sanchez Bulis
VP, Corporate Controller
Sold621$14.34$8,905
Aug. 10, 2026Gary K. Lee
Chief Scientific Officer
Sold131$14.34$1,879
Aug. 10, 2026Stephen J. Hill
Chief Operating Officer
Sold89$14.34$1,276
Aug. 10, 2026Lynn Seely
President and CEO, director
Sold390$14.34$5,593

Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.

Recent SEC filings

All 22 →
  • SCHEDULE 13G/ANov. 10, 2026, 6:03 p.m. ETView on SEC.gov
  • 4Nov. 5, 2026, 5:35 p.m. ETView on SEC.gov
  • 4Nov. 5, 2026, 5:34 p.m. ETView on SEC.gov
  • 10-QNov. 4, 2026, 4:17 p.m. ETView on SEC.gov
  • 8-KNov. 4, 2026, 4:14 p.m. ETView on SEC.gov

    Results of operations and financial condition · Financial statements and exhibits

    AI summary, unreviewedLyell Immunopharma Q3 2026 net loss widens to $45.5 million as R&D rises; revenue in line at $3 thousand; $80.0 million private placement announced

  • 8-KNov. 4, 2026, 9:05 a.m. ETView on SEC.gov

    Unregistered sales of equity securities

    AI summary, unreviewedLyell Immunopharma Announces $80.0 Million Private Placement of 7,428,040 Shares at $10.77 Per Share

  • 4Oct. 13, 2026, 5:17 p.m. ETView on SEC.gov
  • 4Sept. 10, 2026, 7:31 p.m. ETView on SEC.gov